Genotypic resistance testing of HCV – is there a clinical need?
Persistent infections with the hepatitis C virus (HCV) pose a profound global public health burden. In the past 5 years treatment of chronic hepatitis C has dramatically changed. Novel direct-acting antivirals (DAAs) specifically inhibiting viral enzymes or factors that are essential for the viral r...
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
German Medical Science GMS Publishing House
2016-08-01
|
| Sarja: | GMS Infectious Diseases |
| Aiheet: | |
| Linkit: | http://www.egms.de/static/en/journals/id/2016-4/id000023.shtml |